Sanofi Beats Novo To Buy Ablynx For $4.8B
French pharmaceutical company Sanofi SA has agreed to buy Belgian biotechnology firm Ablynx NV for €3.9 billion ($4.8 billion), topping a $3.1 billion bid by Novo Nordisk AS, the company said...To view the full article, register now.
Already a subscriber? Click here to view full article